Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction

ABSTRACT: Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction

PROVIDER: PRJNA951666 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24049057.fastq.gz	Fastqsanger.gz
	SRR24049057_1.fastq.gz	Fastqsanger.gz
	SRR24049057_2.fastq.gz	Fastqsanger.gz
	SRR24049058.fastq.gz	Fastqsanger.gz
	SRR24049058_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 42

Similar Datasets

Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction

Project description:Two molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) have been proposed: the “Classical” and “Basal-like” subtypes. However, the “molecular” classification has not been applied in real-world clinical practice. This study aimed to establish patient-derived organoids (PDOs) for PDAC and evaluate their application in subtype classification and clinical outcome prediction. We constructed a PDO library for morphologic and RNA-seq analyses and drug response assays in vitro. PDOs of PDAC were established at a high efficiency (> 70%) with at least 100,000 live cells. Morphologically, PDOs were classified as gland-like structures (GL type) or densely proliferating inside (DP type). RNA-seq analysis revealed that the “morphological” subtype (GL vs. DP) roughly corresponded to the “molecular” subtype (“Classical” vs. “Basal-like”). The proposed “morphological” classification predicted clinical treatment response and prognosis; the median overall survival of patients with GL type were significantly longer than that of those with DP type (P < 0.005). The GL type showed a better response to gemcitabine than the DP type in vitro, whereas the drug response of the DP type was improved by the combination of ERK and autophagy inhibition. PDAC PDOs facilitated subtype determination and clinical outcome prediction, thereby advancing precision medicine for PDAC.

2024-04-11 | GSE228801 | GEO

Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.

Project description:BackgroundRecently, two molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) have been proposed: the "Classical" and "Basal-like" subtypes, with the former showing better clinical outcomes than the latter. However, the "molecular" classification has not been applied in real-world clinical practice. This study aimed to establish patient-derived organoids (PDOs) for PDAC and evaluate their application in subtype classification and clinical outcome prediction.MethodsWe utilized tumor samples acquired through endoscopic ultrasound-guided fine-needle biopsy and established a PDO library for subsequent use in morphological assessments, RNA-seq analyses, and in vitro drug response assays. We also conducted a prospective clinical study to evaluate whether analysis using PDOs can predict treatment response and prognosis.ResultsPDOs of PDAC were established at a high efficiency (> 70%) with at least 100,000 live cells. Morphologically, PDOs were classified as gland-like structures (GL type) and densely proliferating inside (DP type) less than 2 weeks after tissue sampling. RNA-seq analysis revealed that the "morphological" subtype (GL vs. DP) corresponded to the "molecular" subtype ("Classical" vs. "Basal-like"). The "morphological" classification predicted the clinical treatment response and prognosis; the median overall survival of patients with GL type was significantly longer than that with DP type (P < 0.005). The GL type showed a better response to gemcitabine than the DP type in vitro, whereas the drug response of the DP type was improved by the combination of ERK inhibitor and chloroquine.ConclusionsPDAC PDOs help in subtype determination and clinical outcome prediction, thereby facilitating the bench-to-bedside precision medicine for PDAC.

| S-EPMC11217054 | biostudies-literature

ncRNA expression-based, individualized outcome prediction for CRC patients

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling of ncRNAs in 165 CRC cases.

2016-12-28 | GSE92928 | GEO

Gene expression-based, individualized outcome prediction for autism

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling of 91 up-regulated and 67 down-regulated miRNAs in 5 autism spectrum disorder (ASD) cases and 5 controls.

2015-04-17 | GSE67979 | GEO

Gene expression-based, individualized cancer progression outcome prediction for S61 stable transfectants

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling in stable transfectants

2016-04-26 | GSE80641 | GEO

Gene silenced-based, individualized cancer progression outcome prediction for shATMIN stable transfectants

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling in stable transfectants

2019-05-25 | GSE81866 | GEO

Gene expression-based, individualized outcome prediction for RUNX1T1 Knock-down treated ECFCs

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling of RUNX1T1 mediated.

2017-08-17 | GSE86594 | GEO

MiRNA-expression based, individualized outcome prediction for the cardiovascular disease patients

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling of a total of 2,500 miRNAs in 13 cardiovascular disease patients and 5 healthy controls

2014-05-04 | GSE53675 | GEO

Transcriptional signatures derived from murine tumor-associated macrophages predict outcome in breast cancer patients

Project description:Macrophages are frequently the most abundant immune cells in murine and human cancers. Studies in various transgenic mouse tumor models have revealed pro-tumor functions of tumor-associated macrophages (TAMs), but despite their association with poor clinical outcome in human patients, molecular signatures for the prediction of clinical outcome in humans are still missingbeen demonstrated. Here we generated molecular signatures from F4/80+CD11b+ TAMs from two transgenic breast cancer models: K14cre;Cdh1flox/flox;Trp53flox/flox (KEP), which resembles human invasive lobular carcinoma (ILC) and MMTV-NeuT (NeuT), which resembles HER2-overexpressing breast cancer. Determination of truly specific TAM transcriptome signatures in breast cancer required relationship analysis with healthy mammary gland tissue macrophages (MTMs), since comparison with macrophages from tissues overestimated TAM-specific gene expression. Furthermore, translation of the TAM signatures to outcome prediction in patients required consideration of the breast cancer subtype. TAM signatures derived from the KEP, but not the NeuT model reliably predicted outcome in ILC patients. Collectively, we show that a transgenic mouse tumor model can be utilized to derive a TAM-based signature for human breast cancer outcome prediction and provide a generalizable strategy for determining and applying specific molecular signatures of immune cells to, in principle, any cancer provided the murine model reflects the human disease.

2019-10-30 | GSE126268 | GEO

Gene expression-based, individualized outcome prediction for surgically treated pancreatic cancer patients

Project description:Individualized outcome prediction classifiers were successfully constructed through expression profiling of a total of 8,644 genes in 20 pancreatic cancer cases, which had been consecutively operated.

2024-11-02 | GSE246880 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data